P. L. Pfitzinger Et Al. , "Parasympathomimetic agents inhibit pancreatic cancer growth by suppression of the p44/42 MAPK signalling pathway and increase overall survival," NEUROGASTROENTEROLOGY AND MOTILITY , vol.29, pp.74-75, 2017
Pfitzinger, P. L. Et Al. 2017. Parasympathomimetic agents inhibit pancreatic cancer growth by suppression of the p44/42 MAPK signalling pathway and increase overall survival. NEUROGASTROENTEROLOGY AND MOTILITY , vol.29 , 74-75.
Pfitzinger, P. L., Demir, I. E., Tieftrunk, E., Wang, K., Friess, H., & Ceyhan, G. O., (2017). Parasympathomimetic agents inhibit pancreatic cancer growth by suppression of the p44/42 MAPK signalling pathway and increase overall survival. NEUROGASTROENTEROLOGY AND MOTILITY , vol.29, 74-75.
Pfitzinger, P. Et Al. "Parasympathomimetic agents inhibit pancreatic cancer growth by suppression of the p44/42 MAPK signalling pathway and increase overall survival," NEUROGASTROENTEROLOGY AND MOTILITY , vol.29, 74-75, 2017
Pfitzinger, P. L. Et Al. "Parasympathomimetic agents inhibit pancreatic cancer growth by suppression of the p44/42 MAPK signalling pathway and increase overall survival." NEUROGASTROENTEROLOGY AND MOTILITY , vol.29, pp.74-75, 2017
Pfitzinger, P. L. Et Al. (2017) . "Parasympathomimetic agents inhibit pancreatic cancer growth by suppression of the p44/42 MAPK signalling pathway and increase overall survival." NEUROGASTROENTEROLOGY AND MOTILITY , vol.29, pp.74-75.
@article{article, author={P. L. Pfitzinger Et Al. }, title={Parasympathomimetic agents inhibit pancreatic cancer growth by suppression of the p44/42 MAPK signalling pathway and increase overall survival}, journal={NEUROGASTROENTEROLOGY AND MOTILITY}, year=2017, pages={74-75} }